# Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Study · id `cardio:ct-nct07493304` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07493304](<https://clinicaltrials.gov/study/NCT07493304>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07493304

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1600 participants.

## Technical summary

Registry record NCT07493304. Randomized; no masking; primary purpose treatment. Start 2026-08-26 (actual); primary completion 2031-07-18 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1600 participants (planned count; ClinicalTrials.gov record NCT07493304, source copy `cardio:ctgov-nct07493304-2026-11-05`, retrieved 2026-11-18)
- Started: 2026-08-26 (actual) (ClinicalTrials.gov record NCT07493304, source copy `cardio:ctgov-nct07493304-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2031-07-18 (anticipated) (ClinicalTrials.gov record NCT07493304, source copy `cardio:ctgov-nct07493304-2026-11-05`, retrieved 2026-11-18)
- Completion: 2031-07-18 (anticipated) (ClinicalTrials.gov record NCT07493304, source copy `cardio:ctgov-nct07493304-2026-11-05`, retrieved 2026-11-18)
- Countries: United States; Bulgaria; Japan; Romania; South Korea (ClinicalTrials.gov record NCT07493304, source copy `cardio:ctgov-nct07493304-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07493304-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
- Acronym: ROXI-CAT-II
- Condition: Venous Thromboembolism (VTE)
- Intervention (Drug): REGN7508
- Intervention (Drug): Apixaban
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

## Provenance

Content hash: 515a4bab0362708a3fb8e94235ef397e79666787463250e2d68cb6deee705f5c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
